# Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV

> **NCT02600325** · PHASE3 · COMPLETED · sponsor: **Erasmus Medical Center** · enrollment: 80 (actual)

## Conditions studied

- Acute Hepatitis C
- Human Immunodeficiency Virus
- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir/Elbasvir 100mg/50mg

## Key facts

- **NCT ID:** NCT02600325
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2018-04-01
- **Final completion:** 2019-01-11
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2019-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02600325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02600325, "Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02600325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*